Evolus (EOLS) Competitors $7.68 +0.25 (+3.36%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.76 +0.08 (+0.98%) As of 08/22/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. TVTX, BHVN, AUPH, SDGR, EVO, JANX, ETNB, EWTX, WVE, and ABCLShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Travere Therapeutics (TVTX), Biohaven (BHVN), Aurinia Pharmaceuticals (AUPH), Schrodinger (SDGR), Evotec (EVO), Janux Therapeutics (JANX), 89BIO (ETNB), Edgewise Therapeutics (EWTX), WAVE Life Sciences (WVE), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors Travere Therapeutics Biohaven Aurinia Pharmaceuticals Schrodinger Evotec Janux Therapeutics 89BIO Edgewise Therapeutics WAVE Life Sciences AbCellera Biologics Travere Therapeutics (NASDAQ:TVTX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Is TVTX or EOLS more profitable? Evolus has a net margin of -22.31% compared to Travere Therapeutics' net margin of -50.64%. Travere Therapeutics' return on equity of -717.68% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-50.64% -717.68% -30.69% Evolus -22.31%-759.04%-24.63% Do analysts recommend TVTX or EOLS? Travere Therapeutics presently has a consensus price target of $32.21, indicating a potential upside of 79.77%. Evolus has a consensus price target of $21.25, indicating a potential upside of 176.69%. Given Evolus' higher possible upside, analysts clearly believe Evolus is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87Evolus 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has better valuation & earnings, TVTX or EOLS? Evolus has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$333.87M4.78-$321.55M-$2.04-8.78Evolus$266.27M1.87-$50.42M-$0.98-7.84 Do insiders and institutionals believe in TVTX or EOLS? 90.7% of Evolus shares are owned by institutional investors. 4.2% of Travere Therapeutics shares are owned by insiders. Comparatively, 5.9% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, TVTX or EOLS? Travere Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Does the media prefer TVTX or EOLS? In the previous week, Travere Therapeutics and Travere Therapeutics both had 5 articles in the media. Evolus' average media sentiment score of 1.01 beat Travere Therapeutics' score of 0.86 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEvolus beats Travere Therapeutics on 10 of the 15 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$480.29M$10.84B$5.76B$9.58BDividend YieldN/A1.87%4.41%4.10%P/E Ratio-7.8420.9031.1026.04Price / Sales1.8729.67433.45102.77Price / CashN/A24.5537.7358.48Price / Book-26.483.519.536.61Net Income-$50.42M$211.77M$3.26B$265.56M7 Day Performance14.12%4.44%2.10%1.97%1 Month Performance-19.83%8.85%2.81%-0.36%1 Year Performance-51.58%-9.03%30.56%19.03% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus4.0945 of 5 stars$7.68+3.4%$21.25+176.7%-50.4%$480.29M$266.27M-7.84170TVTXTravere Therapeutics2.4013 of 5 stars$17.28+2.0%$32.21+86.4%+109.1%$1.51B$233.18M0.00460Positive NewsBHVNBiohaven3.8288 of 5 stars$13.42-8.9%$58.46+335.5%-60.9%$1.51BN/A-1.43239Trending NewsAnalyst ForecastOptions VolumeGap UpAUPHAurinia Pharmaceuticals2.6669 of 5 stars$11.43+0.5%$12.00+5.0%+84.5%$1.50B$235.13M22.29300Positive NewsSDGRSchrodinger3.1095 of 5 stars$18.63-3.0%$32.75+75.8%+4.3%$1.41B$207.54M0.00790EVOEvotec1.5578 of 5 stars$3.81-3.1%$5.90+54.9%+17.8%$1.40B$862.40M0.004,827JANXJanux Therapeutics2.089 of 5 stars$22.67-0.7%$91.89+305.3%-45.0%$1.37B$10.59M0.0030ETNB89BIO2.0198 of 5 stars$8.77-4.3%$26.29+199.7%+11.3%$1.34BN/A0.0040EWTXEdgewise Therapeutics2.5965 of 5 stars$12.99+2.4%$40.64+212.8%-24.2%$1.34BN/A0.0060Analyst ForecastWVEWAVE Life Sciences4.7948 of 5 stars$8.10+0.1%$20.27+150.2%+83.9%$1.29B$108.30M0.00240Positive NewsABCLAbCellera Biologics2.2936 of 5 stars$4.50+5.9%$8.00+77.8%+74.9%$1.27B$28.83M0.00500Gap Up Related Companies and Tools Related Companies Travere Therapeutics Competitors Biohaven Competitors Aurinia Pharmaceuticals Competitors Schrodinger Competitors Evotec Competitors Janux Therapeutics Competitors 89BIO Competitors Edgewise Therapeutics Competitors WAVE Life Sciences Competitors AbCellera Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access